Abstract
AbstractThe aggressiveness and limited treatment options make triple‐negative breast cancer (TNBC) a challenging condition to treat. Immune checkpoint blockade therapy, explicitly targeting the programmed death‐ligand 1 (PD‐L1) pathway, is a promising therapeutic approach. However, the effectiveness of PD‐L1 inhibitors like atezolizumab depends on adequate PD‐L1 expression within cancer cells. To this end, this study used nonthermal plasma (NTP) to modulate PD‐L1 in TNBC cells. The current investigation revealed that NTP treatment leads to an upregulation of PD‐L1; this might increase the availability of PD‐L1 to PD‐L1 inhibitors. These findings suggest that shortly NTP could be used as an adjunctive treatment to immunotherapy in TNBC cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
